Alethia Young Sells 1,395 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CFO Alethia Young sold 1,395 shares of Bicycle Therapeutics stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $19,655.55. Following the sale, the chief financial officer now directly owns 45,605 shares in the company, valued at $642,574.45. The trade was a 2.97 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Bicycle Therapeutics Trading Down 0.1 %

NASDAQ BCYC opened at $14.88 on Tuesday. Bicycle Therapeutics plc has a 12 month low of $12.17 and a 12 month high of $28.67. The stock’s fifty day moving average price is $19.27 and its 200-day moving average price is $21.86. The stock has a market cap of $1.03 billion, a P/E ratio of -4.52 and a beta of 0.92.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. The company had revenue of $2.68 million for the quarter, compared to analysts’ expectations of $6.82 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. Bicycle Therapeutics’s revenue was down 50.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.26) EPS. As a group, analysts forecast that Bicycle Therapeutics plc will post -3.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of institutional investors have recently made changes to their positions in BCYC. GAMMA Investing LLC raised its holdings in Bicycle Therapeutics by 105.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after acquiring an additional 1,038 shares during the last quarter. L & S Advisors Inc increased its holdings in shares of Bicycle Therapeutics by 2.4% in the 3rd quarter. L & S Advisors Inc now owns 59,735 shares of the company’s stock worth $1,352,000 after purchasing an additional 1,400 shares in the last quarter. Assetmark Inc. purchased a new position in shares of Bicycle Therapeutics in the third quarter worth $34,000. JPMorgan Chase & Co. lifted its holdings in shares of Bicycle Therapeutics by 26.8% during the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after purchasing an additional 1,782 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Bicycle Therapeutics by 69.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after purchasing an additional 2,918 shares in the last quarter. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Analyst Upgrades and Downgrades

BCYC has been the subject of several research analyst reports. Royal Bank of Canada restated an “outperform” rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a report on Friday, November 1st. Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 price target on shares of Bicycle Therapeutics in a research note on Thursday, October 31st. B. Riley lowered their price objective on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, JMP Securities reduced their target price on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a research report on Wednesday, December 18th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $35.25.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.